Osiris Therapeutics, Inc. Completes $12 Million Private Placement and Eliminates $19 Million of Debt Through Common Stock Conversion

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company, announced today that it has closed an $11.8 million private placement of its common stock and eliminated through conversion, $18.8 million of debt. No fees or commissions were paid in either transaction.
MORE ON THIS TOPIC